Trial · NCT03239145
Results by group18
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 18 of 18
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants Experienced Dose Limit Toxicities (DLT) | [Dose Escalation Dose Level I] Pembrolizumab + Trebananib | 0 | Participants | ||
| Number of Participants Experienced Dose Limit Toxicities (DLT) | [Dose Escalation Dose Level II] Pembrolizumab + Trebananib | 0 | Participants | ||
| Maximum Tolerated Dose (MTD) of Trebananib | [Dose Escalation Dose Level I and Dose Level II] Pembrolizumab + Trebananib | 30 | mg/kg | ||
| Grade 3 or Higher Toxicity Rate in Expansion Cohort | [Dose Expansion Dose Level II] Pembrolizumab + Trebananib (Colorectal) | 59.5 | 90% Confidence Interval 44.6 to 73.1 | percentage of participants | |
| Grade 3 or Higher Toxicity Rate in Expansion Cohort | Dose Expansion Dose Level II] Pembrolizumab + Trebananib (Ovarian) | 63.6 | 90% Confidence Interval 35.0 to 86.5 | percentage of participants | |
| Grade 3 or Higher Toxicity Rate in Expansion Cohort | Dose Expansion Dose Level II] Pembrolizumab + Trebananib (Renal Cell Carcinoma) | 75.0 | 90% Confidence Interval 24.9 to 98.7 | percentage of participants | |
| Objective Response Rate (ORR) | [Dose Level II] Pembrolizumab + Trebananib (Colorectal) | 7.5 | 90% Confidence Interval 2.1 to 18.3 | percentage of participants | |
| Objective Response Rate (ORR) | [Dose Level II] Pembrolizumab + Trebananib (Ovarian) | 9.1 | 90% Confidence Interval 0.1 to 36.4 | percentage of participants | |
| Objective Response Rate (ORR) | [Dose Level II] Pembrolizumab + Trebananib (Renal Cell Carcinoma) | 0 | 90% Confidence Interval 0 to 52.7 | percentage of participants | |
| Progression Free Survival at 6 Months (PFS6) | [Dose Level II] Pembrolizumab + Trebananib (Colorectal) | 13 | 90% Confidence Interval 5 to 25 | percentage probability | |
| Progression Free Survival at 6 Months (PFS6) | [Dose Level II] Pembrolizumab + Trebananib (Ovarian) | 9 | 90% Confidence Interval 1 to 33 | percentage probability | |
| Progression Free Survival at 6 Months (PFS6) | [Dose Level II] Pembrolizumab + Trebananib (Renal Cell Carcinoma) | 50 | 90% Confidence Interval 6 to 84 | percentage probability | |
| Overall Survival at 1 Year (OS1) | [Dose Level II] Pembrolizumab + Trebananib (Colorectal) | 45 | 90% Confidence Interval 28 to 61 | percentage of participants | |
| Overall Survival at 1 Year (OS1) | [Dose Level II] Pembrolizumab + Trebananib (Ovarian) | 80 | 90% Confidence Interval 38 to 95 | percentage of participants | |
| Overall Survival at 1 Year (OS1) | [Dose Level II] Pembrolizumab + Trebananib (Renal Cell Carcinoma) | 50 | 90% Confidence Interval 6 to 84 | percentage of participants | |
| Median Time To Progression (TTP) | [Dose Level II] Pembrolizumab + Trebananib (Colorectal) | 3.1 | 90% Confidence Interval 2.8 to 3.2 | Months | |
| Median Time To Progression (TTP) | [Dose Level II] Pembrolizumab + Trebananib (Ovarian) | 3.1 | 90% Confidence Interval 3.0 to 3.8 | Months | |
| Median Time To Progression (TTP) | [Dose Level II] Pembrolizumab + Trebananib (Renal Cell Carcinoma) | 4.4 | 90% Confidence Interval 1.2 to NA | Months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03239145/results